The subjective sexual arousal scale for men (SSASM): Preliminary development and psychometric validation of a multidimensional measure of subjective male sexual arousal

Journal of Sexual Medicine

Volumn 8, Issue 8, 2011, Pages 2255-2268

  Althof, Stanley E ^a   Perelman, Michael A ^b   Rosen, Raymond C ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

Patient Reported Outcomes; Psychological Assessment of Sexual Dysfunction; Questionnaire; Sexual Arousal

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; ERECTILE DYSFUNCTION; FACTORIAL ANALYSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNAL CONSISTENCY; LIFE SATISFACTION; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; QUESTIONNAIRE; RELIABILITY; SCORING SYSTEM; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL SATISFACTION; SEXUALITY; SUBJECTIVE SEXUAL AROUSAL SCALE FOR MEN; TEST RETEST RELIABILITY; VALIDATION PROCESS;

EID: 79960847504     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02319.x     Document Type: Article

References (52)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
3. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-17.
4. Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Agius PA, Handelsman DJ, de Kretser DM. Men in Australia Telephone Survey (MATeS): A national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 2005;366:218-24.
5. Althof SE. Quality of life and erectile dysfunction. Urology 2002;59:803-10.
6. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.
7. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001;13:192-9.
8. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001;13:2-9.
9. Tan HM, Low WY, Ng CJ, Chen KK, Sugita M, Ishii N, Marumo K, Lee SW, Fisher W, Sand M. Prevalence and correlates of erectile dysfunction (ED) and treatment seeking for ED in Asian men: The Asian Men's Attitudes to Life Events and Sexuality (MALES) study. J Sex Med 2007;4:1582-92.
10. Fisher W, Rosen R, Eardley I, Niederberger C, Nadel A, Kaufman J, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: Understanding PDE5 inhibitor treatment seeking patterns among men with erectile dysfunction. J Sex Med 2004;1:150-60.
11. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: The day after. Eur Urol 2007;51:75-88. discussion 89.
12. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
13. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(4 suppl):S6-S11.
14. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL. Prevalence of erectile dysfunction: A systematic review of population-based studies. Int J Impot Res 2002;14:422-32.
15. Basson R. A model of women's sexual arousal. J Sex Marital Ther 2002;28:1-10.
16. Basson R. The female sexual response: A different model. J Sex Marital Ther 2000;26:51-65.
17. Masters W, Johnson V. Human Sexual Response. Boston, MA: Little and Brown; 1966.
18. Kaplan HS. Hypoactive sexual desire. J Sex Marital Ther 1977;3:3-9.
19. Basson R. Human sex-response cycles. J Sex Marital Ther 2001;27:33-43.
20. Basson R, Althof S, Davis S, Fugl-Meyer K, Goldstein I, Leiblum S, Meston C, Rosen R, Wagner G. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2004;1:24-34.
21. Sachs BD. A contextual definition of male sexual arousal. Horm Behav 2007;51:569-78.
22. Bancroft J. Sexual arousal. In: Polk T, Seifert C, eds. Encyclopedia of cognitive science. London: Wiley; 2002:1165-8.
23. Ferretti A, Caulo M, Del Gratta C, Di Matteo R, Merla A, Montorsi F, Pizzella V, Pompa P, Rigatti P, Rossini PM, Salonia A, Tartaro A, Romani GL. Dynamics of male sexual arousal: Distinct components of brain activation revealed by fMRI. Neuroimage 2005;26:1086-96.
24. Sakheim DK, Barlow DH, Beck JG, Abrahamson DJ. The effect of an increased awareness of erectile cues on sexual arousal. Behav Res Ther 1984;22:151-8.
25. Delizonna LL, Wincze JP, Litz BT, Brown TA, Barlow DH. A comparison of subjective and physiological measures of mechanically produced and erotically produced erections (or, is an erection an erection?). J Sex Marital Ther 2001;27:21-31.
26. Schober JM, Pfaff D. The neurophysiology of sexual arousal. Best Pract Res Clin Endocrinol Metab 2007;21:445-61.
27. Bancroft J. The endocrinology of sexual arousal. J Endocrinol 2005;186:411-27.
28. Rosen RC. Sexual pharmacology in the 21st century. J Gend Specif Med 2000;3:45-52.
29. Carson CC 3rd. Central nervous system-acting agents and the treatment of erectile and sexual dysfunction. Curr Urol Rep 2007;8:472-6.
30. Perelman MA. Clinical application of CNS-acting agents in FSD. J Sex Med 2007;4(4 suppl):280-90.
31. Miner M, Seftel A. Centrally acting mechanisms for the treatment of male sexual dysfunction. Urol Clin North Am 2007;34:483-96.
32. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004;16:51-9.
33. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16:135-42.
34. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
35. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002;14:226-44.
36. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. 2009.
37. Rosen R, Broderick G, Shabsigh R, Swindle R, Lockhart D, Cameron A. Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. J Sex Med 2005;2:461-8.
38. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y, Warner MR, Beardsworth A. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61.
39. Sharlip ID, Shumaker BP, Hakim LS, Goldfischer E, Natanegara F, Wong DG. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: Results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. J Sex Med 2008;5:716-25.
40. Strauss A, Corbin J. Basics of qualitative research: Grounded theory-Procedures and techniques. Newbury Park: Sage Publications; 1990.
41. Hays R, Hayashi T, Stewart A. A five-item measure of socially desirable response set. Educ Psychol Meas 1989;49:629-36.
42. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-8.
43. Cronbach I. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
44. Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006;18:236-50.
45. Perelman MA. The sexual tipping point: A mind/body model for sexual medicine. J Sex Med 2009;6:629-32.
46. Althof SE. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. Int J Impot Res 2002;14(1 suppl):S99-S104.
47. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: The female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2:675-84.
48. Goldstein I, Fisher WA, Sand M, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P, Bangerter K, Bandel TJ, Derogatis LR. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: A prospective, randomized, double-blind, placebo-controlled trial. J Sex Med 2005;2:819-32.
49. Perelman MA. The impact of relationship variables on the etiology, diagnosis and treatment of erectile dysfunction. Adv Prim Care Med Clin Update 2007;3:3-6.
50. Perelman M. Integrated sex therapy: A psychosocial-cultural perspective integrating behavioral, cognitive, and medical approaches. In: Carson CC, Kirby RS, Goldstein I, Wyllie MG, eds. Textbook of erectile dysfunction. London: Informa Healthcare; 2008:298-305.
51. Toledano R, Pfaus J. The Sexual Arousal and Desire Inventory (SADI): A multidimensional scale to assess subjective sexual arousal and desire. J Sex Med 2006;3:853-77.
52. Mosher D, Barton-Henry M, Green S. Subjective sexual arousal and involvement: Development of multiple indicators. J Sex Res 1988;25:412-25.